CLEARWATER, FL, Jan. 5 /PRNewswire-FirstCall/ - Hard to Treat Diseases (HTDS)
www.htdsmedical.com Further to the company's various merger updates where
amongst other things the company addressed several targeted merger candidates,
the company is pleased to announce that it has finalized its bilateral
negotiations with Slavica Bio Chem, www.slavicabiochem.com (Slavica).
Slavica Bio Chem is a spin off of Renuyu Biochem, a USA and a UK company,
founded by Andrea Zecevic. Andrea currently acts as a head scientific advisor
to HTDS. The company research and development dates back to 2005. The
institute and the physical plant is located in Belgrade Serbia. The company
has been completely self funding with private resources since its inception.
Over the next several weeks Slavica management and its officers intend to
provide a series of filings and updates on the company's efforts and progress
in this field.
Under the agreement the medical team will receive payment in stock and options
on HTDS security on a delivery and performance based schedule. Consideration
for Slavica is 300 million non-dilatable restricted shares to be distributed
amongst all doctors involved in Belgrade Serbia research. Andrea Zecevic, as a
vote of confidence in Slavica and who spearheaded the transaction, shall
receive no stock in this transaction and in lieu will take stock options at a
.03c strike price for up to 9% of the company common stock.
In other corporate news, the company representatives intend to visit mainland
China for a second merger company discussions with a China based company in a
similar field and research as Slavica with a significant operations already in
place in China. Upon completion of the China merger, the company intends to
name its new CEO, officers and directors consisting primarily of medical
professionals and business consultants.
The company will provide further details as they become available.
Safe Harbor statement under the Private Securities Litigation Reform Act of
1995: Certain information contained in this release contains forward-looking
statements that involve risk and uncertainties, including but not limited to,
those relating to development and expansion activities, domestic and global
conditions, and market competition.
CONTACT: For scientific dialogue and inquiry only contact Andrea Rubio Zecevic
via e-mail at azconsulting2001@gmail.com. For any corporate matters the
readers should contact the company directly at corporate@htdsmedical.com
CONTACT: For scientific dialogue and inquiry only contact Andrea Rubio Zecevic
via e-mail at azconsulting2001@gmail.com. For any corporate matters the
readers should contact the company directly at corporate@htdsmedical.com
SOURCE Hard to Treat Diseases
For scientific dialogue and inquiry only contact Andrea Rubio Zecevic via
e-mail at azconsulting2001@gmail.com. For any corporate matters the readers
should contact the company directly at corporate@htdsmedical.com
